{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:30:45Z","timestamp":1786991445818,"version":"build-2736575974"},"reference-count":48,"publisher":"Wiley","issue":"5S","license":[{"start":{"date-parts":[[2014,1,13]],"date-time":"2014-01-13T00:00:00Z","timestamp":1389571200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["alz-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Alzheimer's &amp;amp; Dementia"],"published-print":{"date-parts":[[2014,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In this study we assessed increased cortisol in Alzheimer's disease (AD) patients. The selective 11\u2010\u03b2\u2010hydroxysteroid dehydrogenase type 1 (HSD\u20101) inhibitor ABT\u2010384 blocked regeneration of active cortisol and this tests the hypothesis that intracellular hypercortisolism contributes to cognitive impairment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this double\u2010blind, placebo\u2010 and active\u2010controlled phase II study we examine the efficacy and safety of ABT\u2010384 given 10 mg or 50 mg once daily, donepezil 10 mg once daily, or placebo for 12 weeks in subjects with mild\u2010to\u2010moderate AD. The primary efficacy end point was the change from baseline to final evaluation on the 13\u2010item Alzheimer's Disease Assessment Scale\u2013Cognitive subscale (ADAS\u2010Cog) total score.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The study was terminated for futility after randomization of 267 subjects. ABT\u2010384 did not improve ADAS\u2010Cog scores or any secondary end point; however, donepezil significantly improved both cognition and functional end points. Overall incidence of adverse events was similar among treatment groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>ABT\u2010384, when tested at doses associated with complete brain HSD\u20101 inhibition, did not produce symptomatic improvement in AD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1016\/j.jalz.2013.09.010","type":"journal-article","created":{"date-parts":[[2014,1,10]],"date-time":"2014-01-10T17:03:58Z","timestamp":1389373438000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Efficacy and safety evaluation of HSD\u20101 inhibitor ABT\u2010384 in Alzheimer's disease"],"prefix":"10.1002","volume":"10","author":[{"given":"Gerard J.","family":"Marek","sequence":"first","affiliation":[{"name":"Global Pharmaceutical R&amp;D AbbVie, Inc. North Chicago IL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Katz","sequence":"additional","affiliation":[{"name":"Global Pharmaceutical R&amp;D AbbVie, Inc. North Chicago IL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Meier","sequence":"additional","affiliation":[{"name":"Global Pharmaceutical R&amp;D AbbVie, Inc. North Chicago IL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"IV","given":"Nicholas","family":"Greco","sequence":"additional","affiliation":[{"name":"Global Pharmaceutical R&amp;D AbbVie, Inc. North Chicago IL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wuyan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Global Pharmaceutical R&amp;D AbbVie, Inc. North Chicago IL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Liu","sequence":"additional","affiliation":[{"name":"Global Pharmaceutical R&amp;D AbbVie, Inc. North Chicago IL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Lenz","sequence":"additional","affiliation":[{"name":"Global Pharmaceutical R&amp;D AbbVie, Inc. North Chicago IL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,1,13]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)16499-4"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1517\/14740330802528420"},{"key":"e_1_2_6_4_2","first-page":"211","article-title":"Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta\u2010analysis","volume":"3","author":"Hansen R.A.","year":"2008","journal-title":"Clin Interv Aging"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2007.11.071"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.143.3.300"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0197-4580(97)80309-0"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-3223(95)00318-5"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-2010-100663"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurobiolaging.2007.07.007"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.2797-06.2006"},{"key":"e_1_2_6_12_2","doi-asserted-by":"crossref","first-page":"e201","DOI":"10.1016\/j.neurobiolaging.2010.09.010","article-title":"11beta\u2010hydroxysteroid dehydrogenase type 1, brain atrophy and cognitive decline","volume":"33","author":"MacLullich A.M.","year":"2012","journal-title":"Neurobiol Aging"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.4402-09.2010"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.4046-10.2011"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.2783-10.2010"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.2190-07.2007"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0306996101"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2009.04981.x"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002130051057"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(02)01750-X"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1017\/S1355617707070051"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.5"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.284.23.3043"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.34.7.939"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/0022-3956(75)90026-6"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-3223(88)90038-8"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1975.00490510088009"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.141.11.1356"},{"issue":"2","key":"e_1_2_6_29_2","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1097\/00002093-199700112-00003","article-title":"Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study","volume":"11","author":"Mohs R.C.","year":"1997","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/gps.930101208"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.44.12.2308"},{"key":"e_1_2_6_32_2","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1212\/WNL.48.5_Suppl_6.10S","article-title":"The Neuropsychiatric Inventory: assessing psychopathology in dementia patients","volume":"48","author":"Cummings J.L.","year":"1997","journal-title":"Neurology"},{"issue":"2","key":"e_1_2_6_33_2","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1097\/00002093-199700112-00005","article-title":"An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study","volume":"11","author":"Galasko D.","year":"1997","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"e_1_2_6_34_2","first-page":"21","article-title":"Quality of life in Alzheimer's disease: patient and caregiver reports","volume":"5","author":"Logsdon R.G.","year":"1999","journal-title":"J Mental Health Aging"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e31817efbac"},{"key":"e_1_2_6_36_2","unstructured":"MedDRA Maintenance and Support Services Organization. Medical dictionary for regulatory activities (MedDRA) version 14.0;\u00a02011."},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-2011-101554"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1159\/000318845"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1002\/gps.2562"},{"issue":"1","key":"e_1_2_6_40_2","first-page":"CD001190","article-title":"Donepezil for dementia due to Alzheimer's disease","author":"Birks J.,","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"e_1_2_6_41_2","first-page":"CD001191","article-title":"Rivastigmine for Alzheimer's disease","author":"Birks J.","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"e_1_2_6_42_2","first-page":"CD001747","article-title":"Galantamine for Alzheimer's disease and mild cognitive impairment","author":"Loy C.,","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"e_1_2_6_43_2","first-page":"CD003154","article-title":"Memantine for dementia","author":"McShane R.","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2012.05.2091"},{"key":"e_1_2_6_45_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.54.3.588"},{"key":"e_1_2_6_46_2","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-2011-110224"},{"key":"e_1_2_6_47_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2011.01375.x"},{"key":"e_1_2_6_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jash.2011.01.009"},{"key":"e_1_2_6_49_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-2315"}],"container-title":["Alzheimer's &amp; Dementia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1552526013028458?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1552526013028458?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1016%2Fj.jalz.2013.09.010","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1016\/j.jalz.2013.09.010","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1016\/j.jalz.2013.09.010","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1016\/j.jalz.2013.09.010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T18:45:02Z","timestamp":1759862702000},"score":1,"resource":{"primary":{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/10.1016\/j.jalz.2013.09.010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,13]]},"references-count":48,"journal-issue":{"issue":"5S","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["10.1016\/j.jalz.2013.09.010"],"URL":"https:\/\/doi.org\/10.1016\/j.jalz.2013.09.010","archive":["Portico"],"relation":{},"ISSN":["1552-5260","1552-5279"],"issn-type":[{"value":"1552-5260","type":"print"},{"value":"1552-5279","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,13]]},"assertion":[{"value":"2014-01-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}